Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancer.
Donswijk ML, Ettema RH, Meijer D, Wondergem M, Cheung Z, Bekers EM, van Leeuwen PJ, van den Bergh RCN, van der Poel HG, Vis AN, Oprea-Lager DE. Donswijk ML, et al. Among authors: wondergem m. Eur J Nucl Med Mol Imaging. 2024 May;51(6):1741-1752. doi: 10.1007/s00259-024-06594-0. Epub 2024 Jan 26. Eur J Nucl Med Mol Imaging. 2024. PMID: 38273003 Free PMC article.
[A woman with gingival enlargement].
Castelijn DAR, Wondergem MJ, Heijink DM. Castelijn DAR, et al. Among authors: wondergem mj. Ned Tijdschr Geneeskd. 2021 Feb 3;165:D5632. Ned Tijdschr Geneeskd. 2021. PMID: 33651523 Dutch.
Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for 18F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer.
Jansen BHE, Jansen RW, Wondergem M, Srbljin S, de Klerk JMH, Lissenberg-Witte BI, Vis AN, van Moorselaar RJA, Boellaard R, Hoekstra OS, Oprea-Lager DE. Jansen BHE, et al. Among authors: wondergem m. J Nucl Med. 2020 Feb;61(2):210-216. doi: 10.2967/jnumed.118.222513. Epub 2019 Sep 3. J Nucl Med. 2020. PMID: 31481580 Free article.
Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy.
Jansen BHE, van Leeuwen PJ, Wondergem M, van der Sluis TM, Nieuwenhuijzen JA, Knol RJJ, van Moorselaar RJA, van der Poel HG, Oprea-Lager DE, Vis AN. Jansen BHE, et al. Among authors: wondergem m. Eur Urol Oncol. 2021 Oct;4(5):821-825. doi: 10.1016/j.euo.2020.01.002. Epub 2020 Feb 20. Eur Urol Oncol. 2021. PMID: 32088155
18F-DCFPyL PET/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy.
Wondergem M, van der Zant FM, Broos WAM, Roeleveld TA, Donker R, Ten Oever D, Geenen RWF, Knol RJJ. Wondergem M, et al. Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):521-531. doi: 10.1007/s00259-020-04782-2. Epub 2020 Jul 27. Eur J Nucl Med Mol Imaging. 2021. PMID: 32719916
Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial.
Jansen BHE, Bodar YJL, Zwezerijnen GJC, Meijer D, van der Voorn JP, Nieuwenhuijzen JA, Wondergem M, Roeleveld TA, Boellaard R, Hoekstra OS, van Moorselaar RJA, Oprea-Lager DE, Vis AN. Jansen BHE, et al. Among authors: wondergem m. Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):509-520. doi: 10.1007/s00259-020-04974-w. Epub 2020 Aug 12. Eur J Nucl Med Mol Imaging. 2021. PMID: 32789599 Free PMC article. Clinical Trial.
Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer.
Meijer D, Jansen BHE, Wondergem M, Bodar YJL, Srbljin S, Vellekoop AE, Keizer B, van der Zant FM, Hoekstra OS, Nieuwenhuijzen JA, Dahele M, Vis AN, Oprea-Lager DE. Meijer D, et al. Among authors: wondergem m. PLoS One. 2020 Oct 6;15(10):e0239414. doi: 10.1371/journal.pone.0239414. eCollection 2020. PLoS One. 2020. PMID: 33021980 Free PMC article.
107 results